Articles by Erica L. Mayer, MD, MPH
Dual Biomarkers and Treatment Sequencing in HR+/HER2− mBC
BySeth Wander, MD, PhD,Erica L. Mayer, MD, MPH,Kathryn Post, PhD, RN, ANP-BC,Jennifer Hutchinson, PharmD, BCOP The panel explores treatment selection for patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC) harboring both ESR1 and PI3K pathway alterations, emphasizing the need to individualize therapy according to disease biology, pace, symptoms, and treatment tolerability.
ESR1-Directed Treatment Options in HR+/HER2− mBC
BySeth Wander, MD, PhD,Erica L. Mayer, MD, MPH,Kathryn Post, PhD, RN, ANP-BC,Jennifer Hutchinson, PharmD, BCOP The panel shifts to treatment strategies for patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC) who develop an ESR1 mutation after progression on an aromatase inhibitor plus CDK4/6 inhibitor.
Erica L. Mayer, MD, MPH, discussed the practical questions clinicians must answer as the SERENA-6 early-switch approach with camizestrant enters practice.
Erica L. Mayer, MD, MPH, explained why oncologists should switch to camizestrant at ESR1 mutation emergence rather than reserve oral SERDs for progression.
Toxicity Management of PI3K Pathway Inhibitors in HR+/HER2− mBC
BySeth Wander, MD, PhD,Erica L. Mayer, MD, MPH,Kathryn Post, PhD, RN, ANP-BC,Jennifer Hutchinson, PharmD, BCOP Clinicians weigh alpelisib’s hyperglycemia, rash, diarrhea and increasingly favor capivasertib for lower glucose risk with close monitoring.
Treatment Strategies for Biomarker-Negative and PI3K-Pathway Altered HR+/HER2− mBC
BySeth Wander, MD, PhD,Erica L. Mayer, MD, MPH,Kathryn Post, PhD, RN, ANP-BC,Jennifer Hutchinson, PharmD, BCOP Explore evolving options for biomarker-negative metastatic breast cancer, from CDK4/6 rechallenge to gadeptolizumab and PAM-pathway targeted therapy.
Biomarker Testing and Treatment Selection in HR+/HER2− mBC
BySeth Wander, MD, PhD,Erica L. Mayer, MD, MPH,Kathryn Post, PhD, RN, ANP-BC,Jennifer Hutchinson, PharmD, BCOP Learn how liquid and tissue biopsies uncover ESR1 and PI3K mutations to personalize metastatic breast cancer second-line therapy choices.
Second-Line Treatment Considerations in HR+/HER2− mBC
BySeth Wander, MD, PhD,Erica L. Mayer, MD, MPH,Kathryn Post, PhD, RN, ANP-BC,Jennifer Hutchinson, PharmD, BCOP Learn how biomarker testing guides second-line choices after CDK4/6 therapy in HR+ HER2- metastatic breast cancer, including PI3K/AKT/mTOR options.
107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)
ByAdam M. Brufsky, MD, PhD,François-Clément Bidard,Erica L. Mayer, MD, MPH,Yeon Hee Park,Wolfgang Janni,Cynthia X. Ma, MD, PhD,Massimo Cristofanilli, MD,Giampaolo Bianchini,Kevin Kalinsky, MD, MS,Hiroji Iwata,Stephen Chia,Peter A. Fasching,Zbigniew Nowecki,Javier Pascual,Einav Nili Gal-Yam,Wei-Pang Chung,Seock-Ah Im,Alberto Zambelli,Florence Dalenc,Mafalda Oliveira,Steven Fox,Manuel Selvi Miralles,Christopher Morrow,Cynthia Huang Bartlett,Nicholas C. Turner, MD 
Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study
ByPooja Advani, MBBS, MD,Sofia Braga,Adam M. Brufsky, MD, PhD,Karthik V. Giridhar,Erica L. Mayer, MD, MPH,Kelly E. McCann,Ruth M. O’Regan,Cristina Saura,Seth A. Wander,Georg F. Bischof,Beth H. Lowenthal,Judith D. Bebchuk,Lisa D. Eli,Brian G. Barnett,Joyce A. O’Shaughnessy,Tufia C. Haddad 
24 Patient Preferences for CDK4/6 Inhibitor Treatments in HR+/HER2– Early Breast Cancer: A Discrete Choice Survey Study
ByErica L. Mayer, MD, MPH,Mary Lou Smith,Annie Guérin,Dominick Latrémouille-Viau,Nisha C. Hazra,Yan Meng,Wendi Qu,Remi Bellefleur,Vaidyanathan Ganapathy,Liz Santarsiero,Robert Morlock,Maryam Lustberg 
7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor
ByAdam M. Brufsky, MD, PhD,Hannah M. Linden, MD,Hope S. Rugo, MD,Joyce A. O’Shaughnessy,Robert H. Getzenberg,K. Gary Barnette,Domingo Rodriguez,Mitchell Steiner,Erica L. Mayer, MD, MPH 
The expert explained her research focused on the role of CDK4/6 inhibitors in treating breast cancer.
